Skip to main content
Bodoky Gyorgy - vastagbeldaganat onkologiai kezelese


1. Burmeister BH, Schache D, Burmeister EA, Bell A, Poulsen MG, Walpole ET, Mackintosh J.: Synchronous
postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum. Int J Colorectal Dis. 2004
Jan;19(1):55-9. Epub 2003 May 17.
2. Martin RC, Edwards MJ, McMasters KM.: Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the
management of colorectal cancer metastatic to the liver. Am. J. Surg. 2004 Dec;188(6):714-21.
Elsővonalbeli kezelés
3. Idelevich E, Man S, Lavrenkov K, Gluzman A, Geffen DB, Shani A.: Irinotecan combined with bolus 5-fluorouracil and
folinic acid for metastatic colorectal cancer: is this really a dangerous treatment? J Chemother. 2004 Oct;16(5):487-90.
4. Sorbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Ogreid D, Dahl O.: Multicenter phase II
study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic
colorectal cancer. J Clin Oncol. 2004 Jan 1;22(1):31-8.
5. Gil-Delgado MA, Bastian G, Guinet F, Spano JP, Taillibert S, Rocher MA, Castaing D, Adam R, Urien S, Bismuth H,
Khayat D.: Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal
cancer patients. Am J Clin Oncol. 2004 Jun;27(3):294-8.
6. Zondor SD, Medina PJ.: Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann.
Pharmacother. 2004 Jul-Aug;38(7-8):1258-64.
Másodvonalbeli kezelés
7. Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T,
Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC, Palmer PA.: Phase III double-blind placebo-controlled study of
farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol. 2004 Oct
8. Correale P, Messinese S, Caraglia M, Marsili S, Piccolomini A, Petrioli R, Ceciarini F, Micheli L, Nencini C, Neri A,
Vuolo G, Guarnieri A, Abbruzzese A, Prete SD, Giorgi G, Francini G.: A novel biweekly multidrug regimen of
gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal
carcinoma. Br. J. Cancer. 2004 May 4;90(9):1710-4.
9. Louvet C, Andre T, Gamelin E, Garcia ML, Saavedra A, Lenaers G, de Gramont A, Mery-Mignard D, Kalla S.: A
phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic
colorectal cancer patients. Bull Cancer. 2004 Dec;91(12):279-84.
Harmadvonalbeli kezelés
10. Benavides M, Garcia-Alfonso P, Cobo M, Munoz-Martin A, Gil-Calle S, Carabantes F, Villar E, Graupera J,
Balcells M, Perez-Manga G.: Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status
patients with advanced colorectal cancer. Med Oncol. 2004;21(3):255-62.
11. Croles N, Smorenburg CH, van Groeningen CJ, Giaccone G, Boven E.: FOLFOX3 in heavily pretreated patients with
metastatic colorectal cancer. Neth J Med. 2004 Jul-Aug;62(7):242-5.
12. Feliu J, Vicent JM, Garcia-Giron C, Constela M, Fonseca E, Aparicio J, Lomas M, Anton-Aparicio L, Dorta FJ,
Gonzalez-Baron M: Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br. J.
Cancer. 2004 Nov 15;91(10):1758-62.
13. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H,
Satoh A.: Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer. 2004 Jun 1;100(11):2355-
Oralis költséghatékonyság
14. Jansman FG, Postma MJ, van Hartskamp D, Willemse PH, Brouwers JR.: Cost-benefit analysis of capecitabine
versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther. 2004 Apr;26(4):579-
Neoadjuvans kezelés
15. Read TE, Andujar JE, Caushaj PF, Johnston DR, Dietz DW, Myerson RJ, Fleshman JW, Birnbaum EH, Mutch
MG, Kodner IJ.: Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status.
Dis Colon Rectum. 2004 Jun;47(6):825-31. Epub 2004 Apr 19.
16. Bonnen M, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M, Hoff PM, Lin E, Eng C, Wong A,
Janjan NA, Feig BW.: Long-term results using local excision after preoperative chemoradiation among selected T3 rectal
cancer patients. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1098-105.
17. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess
CF, Karstens JH, Liersch T, Schmidberger H, Raab R: Preoperative versus postoperative chemoradiotherapy for rectal
cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40.
18. Capirci C, Rubello D, Chierichetti F, Crepaldi G, Carpi A, Nicolini A, Mandoliti G, Polico C.: Restaging after
neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother. 2004
19. Laudani A, Gebbia V, Leonardi V, Savio G, Borsellino N, Cusimano MP, Calabria C, Stefano R, Agostara B.:
Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.
Anticancer Res. 2004 Mar-Apr;24(2C):1139-42.
20. Chen VM, Thrift KM, Morel-Kopp MC, Jackson D, Ward CM, Flower RL.: An immediate hemolytic reaction
induced by repeated administration of oxaliplatin. Transfusion. 2004 Jun;44(6):838-43.
21. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA.: Recurrence and outcomes
following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann.
Surg. 2004 Jun;239(6):818-25.
22. Ji ZL, Peng SY, Yuan AJ, Li PJ, Zhang W, Yu Y.: Hepatic resection for metastasis from colorectal cancer. Tech
Coloproctol. 2004 Nov;8 Suppl 1:s47-9.
23. Harisi R, Bodoky G, Borsodi M, Flautner L, Weltner J.: Rectal cancer therapy: decision making on basis of quality of
life? Zentralbl Chir. 2004 Apr;129(2):139-48.
24. Tang R, Wang JY, Fan CW, Tsao KC, Chen HH, Wu CM, Chen JS, Changchien CR, Hsieh LL.: p53 is an
independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction
between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett. 2004 Jul 8;210(1):101-9.
25. Rosati G, Chiacchio R, Reggiardo G, De Sanctis D, Manzione L.: Thymidylate synthase expression, p53, bcl-2, Ki-67
and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol. 2004 Sep-Dec;25(5-6):258-
26. Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, Montemurro S, Giuliani F, Maiello E, Colucci G.:
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in
advanced colorectal cancer patients. Int J Cancer. 2004 Aug 20;111(2):252-8.
27. Chapusot C, Martin L, Puig PL, Ponnelle T, Cheynel N, Bouvier AM, Rageot D, Roignot P, Rat P, Faivre J, Piard
F.: What is the best way to assess microsatellite instability status in colorectal cancer? Study on a population base of 462
colorectal cancers. Am J Surg Pathol. 2004 Dec;28(12):1553-9.
28. Asano TK, McLeod RS.: Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal
adenomas and carcinomas. Cochrane Database Syst Rev. 2004;(2):CD004079.
29. Barton MB, Gabriel GS, Miles S.: Colorectal cancer patterns of care in the Western Sydney and Wentworth Area Health
Services. ANZ J Surg. 2004 Jun;74(6):406-12.
30. Provenzale D, Gray RN.: Colorectal cancer screening and treatment: review of outcomes research. J Natl Cancer Inst
Monogr. 2004;(33):45-55.
Otthoni chemotherapia
31. Takahashi K, Mori T, Yamaguchi T, Matsumoto H, Miyamoto H, Arai K, Iwasaki Y, Katayanagi S.: The present and
future of home care chemotherapy for patients with advanced and recurrent colorectal cancer. Gan To Kagaku Ryoho. 2004
Dec;31 Suppl 2:154-6.